Skip to content

About us

Tackling the toughest cancers.
Head on.

“OxSonics and its partners are building a rich pipeline of truly revolutionary products designed to provide smarter and better therapies for patients tackling some of the toughest cancers.”
Dr. Colin Story, Co-founder & former CEO

Penetration of anti-cancer agents into and throughout solid tumours is widely recognised as presenting a major limitation to their effectiveness.

SonoTran® is being developed to provide a step-change in the therapeutic index of anti-cancer agents without the development costs or delays associated with drug reformulation. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumour cancers.

Our team.

Allison Jeynes-Ellis

Dr Allison Jeynes MD, FFPM (UK)

Non-Executive Chair

Dr. Marianna Lalla MD PhD MPH CCT (PharmMed., PeadSurg.)

Chief Medical Officer

Gene Saragnese

Non-Executive Director
Dr Dinah Parker RAQA

Dr Dinah Parker

RAQA Director
Colin Story

Dr Colin Story

Co-Founder
Constantin Coussios

Prof. Constantin Coussios OBE FREng

Non-Executive Director & Co-Founder
Matthew Frohn

Dr Matthew Frohn

Non-Executive Director
Glyn Edwards

Glyn Edwards MBE

Executive Director
George Robinson

George Robinson

Board Member

Prof. Fergus Gleeson FRCP FRCR

Clinical Advisor

Prof. Hardev Pandha MB ChB (Birm) FRACP FRCP PhD CSST (Medical Oncology)

Clinical Advisor

Mr Robert Jones

Clinical Advisor

Dr Christian Coviello

Chief Technology Officer & Co-Founder

Nicholas Adams

Chief Business Officer

Prof. Robert Carlisle

Co-Founder

Andrew Mullen MBA

Chief Operating Officer

David Preston

Finance Director

Dr Cliff Rowe

Development Director

Our mission

As a global leader in ultrasound-based drug delivery, OxSonics’ mission is to maximise the potential of existing and emerging therapies for the benefit of patients worldwide.

Our values.

Our story.

OxSonics was founded in 2013 to commercialise ground-breaking technological advances developed over more than ten years at the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL) at the University of Oxford in the UK. BUBBL is an internationally-recognized centre of excellence in therapeutic ultrasound and drug delivery within the Oxford Institute of Biomedical Engineering.

Since 2013, OxSonics has built a world-leading multi-disciplinary product development and commercialisation team that have successfully developed the SonoTran® Platform as a scalable commercial-grade product. We work closely with both medical oncologists and oncology radiologists to ensure our products are directed at the specific patient groups that stand to benefit most but also that our products fit seamlessly into existing patient care pathways in an oncology ward setting.

Today, SonoTran® is being evaluated clinically and we’re working with multiple partners to tackle the toughest cancers, head on.

Our supporters. Our collaborators.

Longwall Ventures

Oxford Technology and Innovations EIS Fund

MMK Capital

Perivoli Innovations

University of Oxford

Wellcome

Innovate UK

Oxford University Hospitals NHS Foundation Trust